Revvity surpasses annual forecasts as high-growth diagnostics drive momentum
Revvity (NYSE:RVTY) reported fourth-quarter and full-year 2025 results on Monday that exceeded Wall Street estimates, bolstered by resilient demand across its life sciences and diagnostics portfolios.



-640x358.jpg&w=3840&q=75)






